Shandong Sanyuan Biotechnology (301206) Fundamentals 2026 — P/E 48.1x, Revenue Analysis | SniperIQ
Shandong Sanyuan Biotechnology (301206) is a CN-listed Consumer Defensive company in Food Confectioners with a market capitalization of ¥4.6B, trading at ¥22.61 on the SHZ. This SniperIQ fundamentals page covers Shandong Sanyuan Biotechnology's valuation (P/E 48.1x, P/B 1.1x), profitability (net margin 12.8%), revenue (¥650M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shandong Sanyuan Biotechnology's market cap?
Shandong Sanyuan Biotechnology (301206) has a market capitalization of approximately ¥4.6B, trading at ¥22.61 on the SHZ. Market cap moves with the live share price.
What is Shandong Sanyuan Biotechnology's P/E ratio?
Shandong Sanyuan Biotechnology's trailing twelve-month P/E ratio is 48.1x, with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is Shandong Sanyuan Biotechnology?
Shandong Sanyuan Biotechnology runs a net profit margin of 12.8%, a gross margin of 16.0%, and an operating margin of 13.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shandong Sanyuan Biotechnology generate?
Shandong Sanyuan Biotechnology reported revenue of ¥650M for fiscal year 2025, with net income of ¥91M and earnings per share (EPS) of 0.46. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shandong Sanyuan Biotechnology pay a dividend?
Shandong Sanyuan Biotechnology offers a trailing dividend yield of about 4.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shandong Sanyuan Biotechnology financially healthy?
Shandong Sanyuan Biotechnology carries a debt-to-equity ratio of 0.00x and a current ratio of 10.56x, with a market beta of 0.63. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shandong Sanyuan Biotechnology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shandong Sanyuan Biotechnology (301206) the key facts are: market cap ¥4.6B, P/E 48.1x, revenue ¥650M, 52-week range 21.81-31.33. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track Shandong Sanyuan Biotechnology's full fundamentals live
Get Shandong Sanyuan Biotechnology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.